The FDA alignment on a BLA submission pathway is the key catalyst, watch for the Part A data readout in Q2 2026 and completion of REVEAL dosing. The wider-than-expected loss and zero revenue are secondary to regulatory progress for a pre-revenue biotech. Monitor for any delays in the PPQ campaign or trial enrollment.
TSHA drugs
TSHA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 6 $6.98entry
- T+1 · 6mo ago −4.44%α −4.11% · $6.67
- T+5 · 6mo ago −1.86%α −2.99% · $6.85
- T+20 · 6mo ago −20.49%α −23.27% · $5.55
- T+60 · 4mo ago −16.05%α −18.11% · $5.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs $2.3M a year ago. The stock will move on the FDA's reaffirmed alignment for a BLA submission for TSHA-102 based on the REVEAL pivotal trial's 6-month interim analysis, with dosing completion expected in Q2 2026.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP net loss per share -$0.12 vs -$0.08 consensus (miss of 50%)
- Revenue was $0, down from $2.3M in Q1 2025
- Net loss widened to $42.4M from $21.5M YoY, driven by $33.8M R&D spend (up 117%)
- Cash and equivalents $276.6M, expected to fund operations into 2028
- FDA reaffirmed alignment on BLA pathway for TSHA-102, including potential submission based on REVEAL 6-month interim analysis
- Dosing completion in REVEAL pivotal and ASPIRE trials expected in Q2 2026
- BLA-enabling PPQ campaign initiated in April 2026, completion expected Q4 2026
- No treatment-related SAEs or DLTs in REVEAL trials as of May 2026 data cutoff
Financial Impact
Net loss of $42.4M in Q1 2026, cash burn rate ~$43M/quarter, with $276.6M cash runway into 2028
Risk Factors
- Clinical trial failure or regulatory setback for TSHA-102
- Cash burn rate may require future dilutive financing if timelines slip
- Competition from other Rett syndrome therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288743 |
Track record
14 reports on TSHA
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
- Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
- Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
- Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
- Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
- May 6, 202627w ago 8-K Neutral 5/10 No price data
- May 6, 202627w ago Press Release Mixed 7/10 Viewing Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
- Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers